Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Michael Teitell, M.D., Ph.D.
Michael Teitell, M.D., Ph.D.

Specialty:

Pathology
Pediatric Pathology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor, Department of Pathology and Laboratory Medicine, Department of Pediatrics
Professor, Biomedical Engineering Interdepartmental Program
Physician and Chief, Pediatric Pathology, Department of Pathology and Laboratory Medicine
Member, Molecular Biology Institute
Member, California NanoSystems Institute
Member, UCLA AIDS Research Institute
Director, JCCC Cancer Nanotechnology Program Area
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Residency:
Clinical Pathology, University of California San Francisco, 1995 - 1997
Anatomic Pathology, Brigham and Women’s Hospital, 1993 - 1995
Fellowship:
Pediatric Pathology, Childrens Hospital Los Angeles, 1997 - 1999
Medical Degree:
M.D., UCLA School of Medicine, 1993
Degree:
Ph.D., UCLA, 1991
M.S., UCLA, 1985
B.S., UCLA, 1985

Certification(s):

Board Certification(s):
Pediatric Pathology, American Board of Pathology, 2001
Anatomic and Clinical Pathology, American Board of Pathology, 1997

Contact Information:

Phone:
(310) 206-6754 Office
(310) 206-6821 Lab
(310) 825-6185 Pediatrics information and referral
(310) 206-5737 Pediatrics admissions
(310) 825-0867 Pediatrics outpatient appointments
(310) 794-9450 Surgical and Pediatric Pathology information and referral
(310) 825-9744 Pediatric Pathology referring physician
(310) 825-1018 Molecular Biology Institute
Email:
Website:

Scientific Interest(s):

Dr. Michael Teitell’s lab is interested in molecular mechanisms of malignant transformation, with an emphasis on germinal center derived B-cell lymphomas. A screen that compared gene expression profiles from B-cell lymphomas in immune deficient versus immune competent settings identified TCL1 as a dysregulated oncogene in a large number of B-cell leukemias and lymphomas. Generation of a TCL1 transgenic mouse, in which TCL1 expression was maintained throughout B- and T-cell development, lead to one of the first genetic models for germinal center B-cell lymphomas and less frequently B- and T-cell chronic lymphocytic leukemias.

Studies in this model and in comparable human tumor samples lead to the elucidation of key aspects of TCL1-driven lymphomagenesis, including companion genetic and epigenetic alterations required for malignant transformation, affected signal transduction pathways, and a mechanism for abnormal avoidance of cell death. Tcl1 was shown in a broad screen by others to be the only verified oncogene that regulates stem cell self-renewal, providing a potential molecular link between so-called cancer stem cells and B-cell lymphoma that our lab is pursuing in studies of stem cells.

Since TCL1 dysregulation is the key for its tumorigenic action, studies on the mechanism of its expression have lead to discovery of a novel gene regulatory program for germinal center B-cells that requires signaling to the transcriptional co-repressor TORC2/CRTC2. This signaling links DNA damage repair sensing, such as occurs during antibody maturation steps in germinal center B-cells, to a major metabolism pathway that controls glucose homeostasis and cell respiration. One current goal is to understand the complex interrelationship between DNA damage, gene regulation, and control of cell metabolism uncovered by this work and to identify key components in this network as targets for therapeutic intervention.

Selected Cancer-Related Publications:

Abraham N, Grubeck-Loebenstein B, Schoenberger SP, Van Kaer L, Kronenberg M, Teitell MA, Cheroutre H. Affinity-Based Selection of Mucosal CD8 Memory T-Cells by an MHC Class I Molecule. Nat Immunol 2011. In press

Sherman MH, Kuraishy AI, Deshpande C, Hong JS, Cacalano NA, Gatti RA, Manis JP, Damore MA, Pellegrini M, Teitell MA. AID-induced genotoxic stress promotes B cell differentiation in the germinal center via ATM and LKB1 signaling. Mol Cell. 2010 Sep 24;39(6):873-85.

Wang G, Chen HW, Oktay Y, Zhang J, Allen EL, Smith GM, Fan KC, Hong JS, French SW, McCaffery JM, Lightowlers RN, Morse HC 3rd, Koehler CM, Teitell MA. PNPASE regulates RNA import into mitochondria. Cell. 2010 Aug 6;142(3):456-67.

Kuraishy AI, French SW, Sherman M, Herling M, Jones D, Wall R, Teitell MA. TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. Proc Natl Acad Sci U S A. 2007; 104(24): 10175-80.

Teitell MA. The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer. 2005 Aug;5(8):640-8.